Cost watchdogs in England and pharma don't always agree, but the sides are celebrating two new deals on Merck KGaA's Mavenclad and Roche's Perjeta.
Ovarian cancer patients who respond to chemo have new treatment options, but a cost watchdog isn’t convinced they're worth the price.
Bringing a new oncology drug to market in the U.S. is expensive, but cost efficiencies can be wrought, especially with multiple indications.
Three months ago, England’s cost watchdogs nixed Sanofi's Gaucher treatment Cerdelga. But they're already singing a different tune.
Just days after announcing plans to ax 500 jobs in Switzerland, Novartis said another 250 jobs will be eliminated in the U.S.
The world's best-selling drug, AbbVie's Humira, isn’t worth its current net price—and isn’t as good at its job as two potential competitors. That’s ICER's conclusion after reviewing rheumatoid arthritis meds.
Pharma makes more from platinum pricing in the U.S. than it spends on research around the world, a new study shows.
New cancer drugs are making the grade with England's notoriously tough cost-effectiveness watchdogs. What's changed?
At long, long last, Roche’s Perjeta has backing from England’s cost-effectiveness watchdogs.
Even though a NICE committee considered Merck’s Keytruda a “life-extending, end-of-life treatment,” certain lung cancer patients in the U.K. won’t have access to the med because the agency isn't sure the drug is cost effective.